PE20061203A1 - Combinacion de xolair con agente inmunosupresor - Google Patents
Combinacion de xolair con agente inmunosupresorInfo
- Publication number
- PE20061203A1 PE20061203A1 PE2006000134A PE2006000134A PE20061203A1 PE 20061203 A1 PE20061203 A1 PE 20061203A1 PE 2006000134 A PE2006000134 A PE 2006000134A PE 2006000134 A PE2006000134 A PE 2006000134A PE 20061203 A1 PE20061203 A1 PE 20061203A1
- Authority
- PE
- Peru
- Prior art keywords
- xolair
- combination
- immunosuppressor
- immunosuppressor agent
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO ANTI-IgE (OMALIZUMAB); B) UN AGENTE INMUNOSUPRESOR SELECCIONADO ENTRE CICLOSPORINA A, AZATIOPRINA, ANTI-IL-8, ADALIMUNAB, HU5C8, OKT3, ENLIMONAB, ENTRE OTROS LOS CUALES SE CARACTERIZAN POR INHIBIR LA ACTIVACION DE LAS CELULAS-T POR CUANDO MENOS DEL 10% . DICHA COMPOSICION INHIBE LA RESPUESTA INMUNE EN EL TRATAMIENTO DE ENFERMEDADES ALERGICAS TALES COMO ASMA ALERGICO, DERMATITIS ATOPICA, ENFERMEDAD PULMONAR OBSTRUCTIVA, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0502358.5A GB0502358D0 (en) | 2005-02-04 | 2005-02-04 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061203A1 true PE20061203A1 (es) | 2006-12-19 |
Family
ID=34355808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000134A PE20061203A1 (es) | 2005-02-04 | 2006-02-02 | Combinacion de xolair con agente inmunosupresor |
Country Status (20)
Country | Link |
---|---|
US (1) | US20080206237A1 (es) |
EP (1) | EP1846031A1 (es) |
JP (1) | JP2008528650A (es) |
KR (1) | KR20070100344A (es) |
CN (1) | CN101111265A (es) |
AR (1) | AR053541A1 (es) |
AU (1) | AU2006210098A1 (es) |
BR (1) | BRPI0607349A2 (es) |
CA (1) | CA2595976A1 (es) |
GB (1) | GB0502358D0 (es) |
GT (1) | GT200600023A (es) |
IL (1) | IL184713A0 (es) |
MA (1) | MA29273B1 (es) |
MX (1) | MX2007009436A (es) |
NO (1) | NO20074497L (es) |
PE (1) | PE20061203A1 (es) |
RU (1) | RU2007132980A (es) |
TN (1) | TNSN07304A1 (es) |
TW (1) | TW200640487A (es) |
WO (1) | WO2006082052A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0607740A2 (pt) * | 2005-02-08 | 2009-09-29 | Novartis Ag | indução de anticorpos antilinfócitos |
CN107488228A (zh) | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
DK2853545T3 (en) * | 2008-09-17 | 2016-08-29 | Xencor Inc | Antibody specific for IgE |
EA201290525A1 (ru) * | 2009-12-18 | 2013-01-30 | Санофи | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения |
RU2658504C9 (ru) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул |
KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
JO3177B1 (ar) * | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
EP3240804A4 (en) | 2014-12-19 | 2019-01-09 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE |
WO2016098356A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
KR20180095740A (ko) | 2015-02-27 | 2018-08-27 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
WO2017106859A1 (en) | 2015-12-18 | 2017-06-22 | University Of Notre Dame Du Lac | Covalent heterobivalent antibody inhibitors and ligands |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
DE102017215154A1 (de) | 2017-08-30 | 2019-02-28 | Markus Bläss | Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-04 GB GBGB0502358.5A patent/GB0502358D0/en not_active Ceased
-
2006
- 2006-01-18 GT GT200600023A patent/GT200600023A/es unknown
- 2006-02-02 WO PCT/EP2006/000911 patent/WO2006082052A1/en active Application Filing
- 2006-02-02 EP EP06706581A patent/EP1846031A1/en not_active Withdrawn
- 2006-02-02 US US11/814,871 patent/US20080206237A1/en not_active Abandoned
- 2006-02-02 BR BRPI0607349-2A patent/BRPI0607349A2/pt not_active Application Discontinuation
- 2006-02-02 CA CA002595976A patent/CA2595976A1/en not_active Abandoned
- 2006-02-02 AR ARP060100378A patent/AR053541A1/es not_active Application Discontinuation
- 2006-02-02 MX MX2007009436A patent/MX2007009436A/es not_active Application Discontinuation
- 2006-02-02 CN CNA2006800039151A patent/CN101111265A/zh active Pending
- 2006-02-02 PE PE2006000134A patent/PE20061203A1/es not_active Application Discontinuation
- 2006-02-02 JP JP2007553536A patent/JP2008528650A/ja active Pending
- 2006-02-02 KR KR1020077017947A patent/KR20070100344A/ko not_active Application Discontinuation
- 2006-02-02 AU AU2006210098A patent/AU2006210098A1/en not_active Abandoned
- 2006-02-02 RU RU2007132980/13A patent/RU2007132980A/ru not_active Application Discontinuation
- 2006-02-03 TW TW095103825A patent/TW200640487A/zh unknown
-
2007
- 2007-07-19 IL IL184713A patent/IL184713A0/en unknown
- 2007-08-03 TN TNP2007000304A patent/TNSN07304A1/en unknown
- 2007-08-28 MA MA30171A patent/MA29273B1/fr unknown
- 2007-09-04 NO NO20074497A patent/NO20074497L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB0502358D0 (en) | 2005-03-16 |
IL184713A0 (en) | 2007-12-03 |
MX2007009436A (es) | 2007-08-17 |
NO20074497L (no) | 2007-10-26 |
CN101111265A (zh) | 2008-01-23 |
AR053541A1 (es) | 2007-05-09 |
BRPI0607349A2 (pt) | 2009-09-01 |
TNSN07304A1 (en) | 2008-12-31 |
US20080206237A1 (en) | 2008-08-28 |
CA2595976A1 (en) | 2006-08-10 |
TW200640487A (en) | 2006-12-01 |
EP1846031A1 (en) | 2007-10-24 |
RU2007132980A (ru) | 2009-03-10 |
JP2008528650A (ja) | 2008-07-31 |
GT200600023A (es) | 2006-08-16 |
MA29273B1 (fr) | 2008-02-01 |
AU2006210098A1 (en) | 2006-08-10 |
KR20070100344A (ko) | 2007-10-10 |
WO2006082052A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20061203A1 (es) | Combinacion de xolair con agente inmunosupresor | |
AR058104A1 (es) | Compuestos organicos | |
CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
AR078346A1 (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
AR049565A1 (es) | Anticuerpos de union a interleuquina 13 humana | |
PE20081506A1 (es) | Formulaciones de ansamicina | |
CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
NO20083630L (no) | Nye pyridinderivater | |
EP2687220A3 (en) | Treatment of inflammatory diseases using placental stem cells | |
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
CR20190073A (es) | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) | |
CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
WO2009029847A8 (en) | Compositions and methods of using proislet peptides and analogs thereof | |
CL2008002411A1 (es) | Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras. | |
AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
CL2008001620A1 (es) | Induccion de fenotipo tolerogenico en celulas dendriticas maduras | |
MY145349A (en) | Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor | |
CR9454A (es) | Tratamiento de Enfermedades del Higado en las cuales el hierro juega un papel en la Patogenesis | |
CL2008002984A1 (es) | Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio. | |
UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
CL2008002380A1 (es) | Composicion farmaceutica de liberacion prolongada que comprende micofenolato sodico, al menos un material de control de liberacion y opcionalmente excipientes; y su uso en el tratamiento de enfermedades que requieren de inmunosupresores, tales como trasplantes, injertos o enfermedades autoinmunes. | |
PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
CL2007003305A1 (es) | Compuestos analogos de adenosina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermdades tales como fibrosis quistica, otitis media, asma, ulcera peptica, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |